Navigation Links
Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
Date:6/12/2008

SAN DIEGO, June 12 /PRNewswire/ -- Recent guidelines published by the Clinical Resource Efficiency Support Team (CREST) provide further support for the use of bioimpedance technology for the early assessment of lymphedema.

The published guidelines for Northern Ireland titled "Guidelines for the Diagnosis, Assessment and Management of Lymphoedema" are the result of an expert panel including patients and healthcare professionals that reviewed the evidence for diagnosing, assessing and treating lymphedema.

The guidelines support the need for a shift in treatment focus from a reactive approach to one focused on the early assessment and early intervention of the condition. Bioimpedance technology featuring high sensitivity and specificity support this approach.

This surveillance method of diagnosis and treatment reflects recommendations recently published online in the journal Cancer, the official journal of the American Cancer Society.

To view the published guidelines online, please visit http://www.crestni.org.uk/crest_guidelines_on_the_diagnosis__assessment_and _ma nagement_of_lymphoedema.pdf. (Due to the length of the link, please copy and paste into your browser.)

About Lymphedema

Lymphedema is a condition that can cause significant swelling of the upper and lower extremities due to the build-up of excess lymph fluid. This can occur when the lymphatic system, which is responsible for draining excess fluid from the body and is a key component of the immune system, is damaged or altered. In breast cancer patients, this can occur after surgery, such as removal or biopsy of the lymph nodes, and/or radiation therapy. It is estimated that 6 percent to 40 percent of patients with breast cancer develop lymphedema, and that it often occurs within the first two years after surgery. For some cancer survivors and others at risk, a low level lymphedema can occur 10 years to 15 years following the initial primary treatment and develop into a condition that has a serious impact on overall health and quality of life. For more information about lymphedema, visit http://www.nci.nih.gov/cancerinfo/pdq/supportivecare/lymphedema/patient/.

About ImpediMed

ImpediMed is the world leader in the development and distribution of medical devices employing Bioimpedence Spectroscopy (BIS) technologies for use in non-invasive screening and monitoring of human disorders and diseases. ImpediMed's primary product range consists of a number of medical devices that enable surgeons, oncologists and radiation oncologists to detect early onset secondary lymphedema in breast cancer survivors, before the onset of symptoms that are detectable using the most commonly used clinical technique, and before the condition becomes a matter of lifelong management and impairs the quality of life of the cancer survivor. ImpediMed has the only medical BIS device with FDA clearance in the United States for the clinical assessment by health care providers of secondary lymphedema of the arm. For more information, visit http://www.impedimed.com.

Contacts: Wendy Lau or David Schull

Russo Partners LLC

(212) 845-4272

wendy.lau@russopartnersllc.com

david.schull@russopartnersllc.com


'/>"/>
SOURCE ImpediMed
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
2. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
3. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
6. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
7. Cardiac Safety Study of Stinger S-200 Published
8. Multi Merci Trial Results Published in Peer Reviewed Journal
9. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... ... 29, 2016 , ... Shamangelic Healing, Sedona Arizona's Premier ... Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness to ... the store is just one more way Shamangelic Healing supports people’s quest for ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global ... Park on Sunday, with sunny skies, a light breeze and temperatures in the 60s. ... , The 5k Run and Walk and 1-mile walk were held to increase ...
Breaking Medicine News(10 mins):